RPR 105735B
Latest Information Update: 22 Feb 1995
At a glance
- Originator Aventis
- Class Antiasthmatics
- Mechanism of Action Leukotriene D4 receptor antagonists
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 17 Feb 1995 Discontinued-Preclinical for Asthma in France (Unknown route)
